GCM
REGN icon

Greenland Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Greenland Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-600
Closed -$577K – 429
2024
Q1 		$577K Buy
+600
New +$571K 0.06% 226

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Greenland Capital Management's REGN Position: Q2 2024 in Review

Greenland Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 351 shares — an estimated $338K sold.

Greenland Capital Management first reported a position in REGN in Q4 2023 and held it in 2 quarters. The position peaked at $338K in Q1 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • Greenland Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Greenland Capital Management sold 351 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $338K.
  • Greenland Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Greenland Capital Management's Regeneron Pharmaceuticals position peaked at $338K in Q1 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Greenland Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.